Answers are grounded in this paper and cite their sources.
Background: Pituitary adenomas are sellar tumors that may enlarge beyond the sella and disturb visual function through compression of the optic apparatus. Macroadenomas can cause visual field loss, reduced visual acuity, impaired color perception, and optic disc pallor when the optic chiasm, optic nerves, or adjacent pathways are involved. Surgical decompression is usually considered when vision is threatened; however, dopamine agonist therapy may be useful in patients with hyperprolactinemia or suspected prolactinoma. Case Presentation: A 23-year-old woman presented with a three-year history of progressive bilateral visual decline, visual field narrowing, and recurrent headache. Serum prolactin was moderately increased, and magnetic resonance imaging demonstrated a pituitary macroadenoma compressing the optic chiasm. Bromocriptine 2.5 mg once daily was initiated while neurosurgical tumor resection was being planned. After one month of treatment, the patient showed improvement in left-eye visual acuity, color vision, and visual field findings. Although surgery remains the preferred approach for pituitary macroadenoma with progressive visual compromise, preoperative medical therapy may provide functional benefit in selected cases. Dopamine D2 receptor expression has been described in several pituitary adenoma subtypes, supporting a possible therapeutic role for dopamine agonists beyond classic prolactinoma. Conclusion: This case demonstrates early visual improvement after dopamine agonist therapy in a patient with pituitary macroadenoma-associated optic pathway compression. Coordinated ophthalmologic, endocrine, and neurosurgical management is essential to preserve visual function, address hormonal abnormalities, and improve patient quality of life.
No takes yet. Share an insight, caveat, or question.
Widyati et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: